SOURCE: BioMedReports

July 20, 2011 08:14 ET

Report: Upcoming Milestones Are Stimulating Interest in Chromadex

LOS ANGELES, CA--(Marketwire - Jul 20, 2011) - A new trade alert issued about ChromaDex Inc. (OTCBB: CDXC) informs investors that a series of near-term catalysts has the emerging biotechnology firm poised for rapid growth and substantially increased revenues.

With $3M in cash, no debt and a market cap of only $115, perhaps even more appealing to speculators is the fact that company insiders have been buying tens of thousands of shares in the open market regularly during the past couple of months.

According to the newly published report, the company also has a pending commercial product launch, complete with an advertisement campaign and the full marketing support of the national retail chain, with others set to follow.

This launch represents just one of several pending milestones. News of the company's growth and the accelerating commercialization is attracting more investors and that may help qualify the company for an up-listing to one of the major exchanges.

The special report on the significance of these developments, including a technical analysis of the stock's latest trading activity is available now at:

In addition, investors interested in accessing BioMedReports' new complete database of clinical trials and upcoming FDA and world-wide regulatory decisions which can be used to make more profitable trades can go to:

News developments and live healthcare sector updates are available constantly via twitter at:

About BioMedReports.Com
BioMedReports is a news portal covering the biomedical news and financial sector. BioMedReports is not paid or compensated to report the news and developments of publicly traded companies in the healthcare sector of the markets. Full disclosures and information about these stocks and news are available at BioMedReports.Com

Contact Information

  • Media Contacts Only:
    Mary Davila
    Assistant Editor,BioMedReports.Com
    e-mail: Email Contact
    Tel: +1 323 472 4480
    Fax: +1 888 210 3556